Abstract P4-11-05: Aromatase inhibitors mediate specific gut-bug interactions to shift the microbiome and decrease inflammation during adjuvant treatment in breast cancer patients
Abstract
Background: Recent studies implicate the gut microbiome as a potential risk factor for breast cancer and a feature modifying anti-cancer drug therapeutic response. However, whether orally administered endocrine-targeting therapies such as aromatase inhibitors (AI) used post-surgery in the adjuvant setting to reduce estrogen receptor-α (ER+) breast cancer recurrence, modify the gut microbiome is unknown. We measure the shift in the gut microbiome and plasma inflammation marker as part of the ongoing Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability clinical trial (NCT05030038).Methods: Eligibility requirements include women with a breast cancer diagnosis after surgical and radiation treatment before being prescribed adjuvant AI therapies. After consenting for trial, women undergo a baseline fecal collection and blood draw before starting their aromatase inhibitor. Patients provided a 4-weeks and 12-weeks fecal sample, along with a 12-weeks blood sample. Fecal DNA was isolated and 12M read depth metagenomic microbiome sequencing was performed. Inflammatory cytokines and other microbial-derived metabolites were measured in plasma using ELISA and metabolomics approaches. Results: Samples from 10 women with matching fecal and plasma specimens were analyzed for microbiome and inflammatory cytokines. Administration of AI did not significantly modify α-diversity or β-diversity measurements. However, we did observe that AI therapy resulted in a…
Read the paper
Related studies
- Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids
- Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome
- Altered gut microbiome composition and function are associated with gut barrier dysfunction in healthy relatives of patients with Crohn's disease
- Diet, obesity, and the gut microbiome as determinants modulating metabolic outcomes in a non-human primate model
- Immune Impairment Associated with Vitamin A Deficiency: Insights from Clinical Studies and Animal Model Research
- Glyphosate-based herbicides influence antioxidants, reproductive hormones and gut microbiome but not reproduction: A long-term experiment in an avian model
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.